Michigan State University
East Lansing, Michigan, 48824, United States
NCT Number: NCT03436628
Type 1 diabetes (T1D) afflicts approximately 154,000 people under the age of 20. Most people with T1D are diagnosed at a young age; their parents have to manage their child's condition. Eventually, the child must begin to take steps to transition to self-management. During the transition from parent to adolescent self-management, difficulties arise because adolescents may not be fully aware of, or want, to take responsibility for all the necessary tasks to successfully manage their T1D. Though there are other apps on the market to help with diabetes care, NONE do what the proposed app will do. The proposed self-management mobile app allows for monitoring the patients' T1D by linking their self-management information to their parents' cell phone, and thus also helps to bridge communication gaps. Prior research suggests that these are critical gaps that must be filled in order for successful transition in care to occur, the proposed app will help fill some of these gaps.
Looking for future studies?
Notify Me10 year–15 year
All sexes
Interventional
Not applicable
East Lansing, Michigan, 48824, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The adolescents must:
The parent/guardian must:
Exclusion criteria
The exclusions for adolescents include:
Exclusion criteria
for both the adolescents and parents/guardians include:
a) a diagnosis of a major psychiatric or neurocognitive disorder (e.g., traumatic brain injury, dementia, schizophrenia, bipolar disorder, borderline personality disorder, and mental retardation).
A mobile phone application
Time frame: Baseline and 3 months
Measured with the Diabetes Behavior Rating Scale (5 point likert scale, never-always); A higher value represents a better outcome
Time frame: Baseline and 3 months
A laboratory test of HbA1c will be collected at the local hospital; A lower value represents a better outcome
Time frame: Baseline and 3 months
Measured with the Multidimensional Scale of Perceived Social Support (5 point likert scale, all of the time-never); A lower value represents a better outcome
Time frame: Baseline and 3 months
Measured using Diabetes Empowerment Scale - Short Form (5-point likert scale, strongly disagree-strongly agree); A higher value represents a better outcome
Time frame: Baseline and 3 months
Measured using PedsQL (5-point likert scale, never-almost always); A higher value represents a better outcome
Time frame: Baseline and 3 months
Measured using Diabetes Family Conflict Scale (3-point likert scale, always-never); A lower value represents a better outcome
Time frame: Baseline
Measured using Alabama Parenting Questionnaire (5-point likert scale, very often-never); Values of this scale vary based on which sub scale is being used. For negative parenting sub scales, a lower value represents a better outcome; and for positive parenting sub scales, a higher value represents a better outcome.
Time frame: Baseline and 3 months
Measured using Parental Monitoring of Diabetes Care Scale (5-point likert scale, always-never); A lower value represents a better outcome
Michigan State University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00358059
Autoimmune Diseases, Behavior
Jacksonville, Florida, United States
View Trial DetailsNCT06599840
Autoimmune Diseases, Behavioral Intervention
Stockholm, Sweden
View Trial DetailsNCT07696039
Autoimmune Diseases, Diabetes Mellitus
Bergamo, Italy
View Trial DetailsNCT03263494
Autoimmune Diseases, Diabetes Mellitus
Los Angeles, California, United States
View Trial Details